$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
奥贝胆酸多少钱?在乌鲁木齐可以购买到吗?
2025-10-19 11:44:20
Check Details
胆管癌靶向新药培米替尼(PEMIGATINIB)的临床研究结果
2025-10-19 11:44:20
Check Details
培米替尼的使用方法和副作用是什么?
2025-10-19 11:44:20
Check Details
培米替尼pemigatinib是治疗胆管癌的靶向药
2025-10-19 11:44:20
Check Details
第二款胆管癌靶向药物—英菲格拉替尼获批上市
2025-10-19 11:44:20
Check Details
英菲格拉替尼的用法用量是怎样的?有什么副作用?
2025-10-19 11:44:20
Check Details
先行先试!近日,胆管癌新药英菲格拉替尼在海南开出首张处方
2025-10-19 11:44:20
Check Details
英菲格拉替尼显示出治疗FGFR2改变的晚期胆管癌的潜力
2025-10-19 11:44:20
Check Details
英菲格拉替尼现在在上海能够买到吗?
2025-10-19 11:44:20
Check Details
英菲格拉替尼Truseltiq治疗胆管癌效果显著
2025-10-19 11:44:20
Check Details
佩米替尼片治疗胆管癌疗效如何?治疗时要注意什么
2025-10-19 11:44:20
Check Details
全球首个!美国FDA批准艾伏尼布用于治疗IDH1突变胆管癌
2025-10-19 11:44:20
Check Details
1
2
...
6107
6108
6109
6110
6111
6112
6113
...
10232
10233
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
2
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
3
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
4
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy
5
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
6
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
7
Fezolinetant (Veozah) Dosing and Liver Monitoring Guide
8
Lusutrombopag Safety and Dosing: Thrombosis Risk and Indications
9
Mirogabalin for Neuropathic Pain: Onset Time and Dosing Strategy
10
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
11
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
12
Anagrelide and Myelofibrosis Risk: Controversy and Monitoring in ET Treatment